Nabilone
Nabilone is a synthetic cannabinoid capsule approved in 1985 for chemotherapy-induced nausea and vomiting that standard drugs cannot control; like dronabinol it is a later-line option because of its effects on mood and balance.
Overview
Nabilone was developed by Eli Lilly and approved by the FDA in December 1985 for nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments; it is also approved in Canada and the United Kingdom. Randomised trials showed it superior to prochlorperazine and placebo, but the serotonin and neurokinin antagonists that followed are more effective. Drowsiness, vertigo, dry mouth and euphoria are common, and it is a controlled substance. It has been studied off label for chronic pain and appetite.
A synthetic THC analogue that activates CB1 receptors in the brain's vomiting centres. Connects to Cannabinoid receptor 1.
1.Nabilone slips into a pocket on Cannabinoid receptor 1.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 1985 | Nausea and vomiting from cancer chemotherapy in patients who have failed conventional antiemetics |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Nabilone" OR ABSTRACT:"Nabilone" OR TITLE:"Cesamet" OR ABSTRACT:"Cesamet") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Nabilone, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentDronabinol
Shares Cannabinoid receptor 1 and the tag chembl-universe.